Mitsubishi UFJ Trust & Banking Corp Purchases 75,982 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 15.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 578,265 shares of the company's stock after acquiring an additional 75,982 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.05% of Teva Pharmaceutical Industries worth $12,745,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of TEVA. Clal Insurance Enterprises Holdings Ltd grew its position in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after buying an additional 4,418,961 shares in the last quarter. Lingotto Investment Management LLP increased its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after buying an additional 688,862 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock valued at $573,822,000 after buying an additional 569,412 shares in the last quarter. State Street Corp lifted its holdings in shares of Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after acquiring an additional 1,778,268 shares during the last quarter. Finally, AustralianSuper Pty Ltd grew its position in Teva Pharmaceutical Industries by 16.8% in the fourth quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company's stock worth $203,268,000 after acquiring an additional 1,329,319 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Trading Up 0.4 %

Shares of TEVA stock traded up $0.06 during mid-day trading on Wednesday, reaching $15.35. The stock had a trading volume of 2,040,667 shares, compared to its average volume of 9,670,990. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock's 50-day moving average price is $16.95 and its two-hundred day moving average price is $18.08. The firm has a market capitalization of $17.40 billion, a PE ratio of -10.53, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the subject of several research analyst reports. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Thursday, March 27th. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Bank of America lowered their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Finally, UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.